Osnuvo · DIN 02495589 · 250 mcg/mL · injection solution-3mL Cart Pk
Limited Use, Reason for Use code 635 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 635 required
Write on scriptReason for Use code 635 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 635
Reason for Use code 635
For the treatment of osteoporosis in patients at a high risk of fragility fractures who meet ALL the following criteria:
- 65 years of age or older; AND
- Has a documented bone mineral density [BMD] T-score of less than or equal to -3; AND
- Has a history of prior fragility fracture(s); AND
- Has used an anti-resorptive agent for osteoporosis which resulted in osteonecrosis of the jaw and/or an atypical femur fracture.
Note: The maximum lifetime exposure to teriparatide for an individual patient is 24 months
Coverage limit:
LU Authorization Period: 2 years
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Teriparatide
Brand(s): Forteo and generics
DOSAGE FORM/ STRENGTH: Please refer to the ODB Formulary for a list of funded
products
Effective with the May 31, 2024 Ontario Drug Benefit Formulary/ Comparative Drug Index
update, Teriparatide as Forteo has transitioned to the ODB formulary with its generic
versions. Also, please note that the Teriparatide biosimilar (Osnuvo) is also publicly
funded as a limited use benefit on the Ontario Drug Benefit formulary effective on
September 29, 2022. Refer to the ODB formulary for the Limited Use Criteria for all
teriparatide products.
401
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 401, record 230, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)No interchangeable product listed in the Ontario extract
Osnuvo · DIN 02495589
Manufacturer: Avir Pharma Inc.; listing date 2022-09-29
Health Canada: Marketed since 2020-10-27 · brand OSNUVO · ATC H05AA02 TERIPARATIDE · form Solution · route Subcutaneous · ingredients TERIPARATIDE 250 MCG/ML · company Avir pharma inc. · schedule Prescription, Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product recordOsnuvo: Formulary list price $565.26 per unit (the source does not state the unit; exact figure $565.2600). What the ministry pays, not the patient.
Ministry pays: $565.2600 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02495589)
Source record
DIN 02495589: Osnuvo
Raw flags: sec12=Y, sec3=Y
Item: 682400015; group id 789; item number 1919; lccId 00361; manufacturer id AVP
Source form: Inj Sol-3mL Cart Pk; strength: 250mcg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $565.2600; ministry $565.2600
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02495589
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98548
Shortage status: not checked (no credentials)